Form 4: Lexicon Pharma Exec Converts RSUs, Sells Shares for Tax

Lexicon Pharmaceuticals' SVP, General Counsel & Secretary, Brian T. Crum, converted restricted stock units into common stock and subsequently sold shares to cover tax obligations.

Summary

• Brian T. Crum, SVP, General Counsel & Secretary of Lexicon Pharmaceuticals, Inc. (LXRX), reported multiple transactions on February 28, 2026.
• Converted a total of 273,006 Restricted Stock Units (RSUs) into common stock.
• Disposed of 105,019 shares of common stock at a price of $1.47 per share to satisfy tax withholding obligations.
• Following these transactions, Mr. Crum directly beneficially owns 428,802 shares of common stock.
• Mr. Crum also directly beneficially owns 409,714 Restricted Stock Units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The RSU conversions are positive as they represent vesting, but the subsequent sale for tax purposes is a routine, non-discretionary transaction.

Positives

• Conversion of Restricted Stock Units into common stock indicates vesting of equity awards, reflecting a standard component of executive compensation.

Negatives

• Disposition of 105,019 shares of common stock, even for tax purposes, represents a reduction in direct share ownership by an insider.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance, as it is a report of past insider transactions.

Industry Context

StockSavvy.ai notes that insider transactions, such as RSU conversions and subsequent tax-related sales, are common occurrences in the biotechnology and pharmaceutical sectors, reflecting standard compensation practices and tax planning for executives. These transactions typically do not indicate a change in the company's strategic direction or operational performance.

Comparison to Industry Standards

• Insider RSU conversions and tax-related sales are standard practice across industries, including biotech. For example, executives at companies like Pfizer or Moderna frequently report similar transactions as part of their compensation plans.
• The disposition of shares to cover tax obligations is a routine event and not indicative of a lack of confidence in the company's future.

Stakeholder Impact

• Shareholders: Minor dilution from RSU conversion, partially offset by the tax sale. Overall, this is a routine event with minimal direct impact on existing shareholders.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions involving the conversion of restricted stock units and subsequent sale of shares to cover tax obligations. Such events are standard compensation practices and do not typically signal a change in the company's fundamentals or future prospects. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an existing investment thesis.

Keywords

Lexicon Pharmaceuticals, LXRX, Form 4, Insider Transaction, Restricted Stock Units, RSU conversion, Stock sale, Tax withholding, Brian T. Crum